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ABSTRACT
Background: Tulobuterol tape is the first long-acting transdermal preparation of a β2-agonist designed to re-
lease tulobuterol in an optimal fashion over a 24-hour period. We investigated the additive effect of tulobuterol
tape in adult asthma patients treated with inhaled corticosteroids.
Methods: A randomized, double-blind, double-dummy, parallel-group, multicenter trial was conducted. Male
and female patients with a diagnosis of asthma requiring inhaled short-acting β2-agonists despite treatment
with inhaled corticosteroids took tulobuterol tape (1 mg or 2 mg) and corresponding placebo tapes for 4 weeks.
Results: Mean morning peak expiratory flows (PEF) in the 1 and 2 mgday groups were significantly in-
creased from the baseline value by 23.8 and 35.9 Lmin at week 4, respectively. The increase in mean morning
PEF in the 2 mgday group was significantly higher than that in the 1 mgday group. The mean evening PEF
was significantly increased in both treatment groups compared with baseline values. Although the increase in
mean evening PEF in the 2 mgday group was greater than that in the 1 mgday group, the difference between
groups was statistically significant only at week 1. The safety profiles of the two treatments were similar.
Conclusions: In patients with persistent asthma who require inhaled short-acting β2-agonists while receiving
inhaled corticosteroids, transdermal tulobuterol significantly improved PEF in a dose-dependent manner, i.e.,
greater effect with 2 mg than with 1 mg per day.
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INTRODUCTION
Chronic airway inflammation plays an essential role
in the pathogenesis of bronchial asthma, and inhaled
corticosteroids are recognized as first-line agents for
the treatment of persistent asthma . 1-3 However ,
monotherapy with inhaled corticosteroids may not
fully control the symptoms or prevent exacerbations
of persistent asthma . International guidelines on
asthma management, therefore, have recommended
that the inhaled long-acting β2-agonists salmeterol
and formoterol should be used as “controllers” and
the inhaled short-acting β2-agonists as “relievers”.1-4
Tulobuterol tape is the first long-acting transder-
mal preparation of a β2-agonist designed to release tu-
lobuterol in an optimal fashion over a 24-hour period.
When it is applied once daily at bedtime, the blood
concentration of tulobuterol does not increase
abruptly , as often occurs with oral preparations ,
peaks early in the morning when respiratory function
usually decreases to its lowest level , and is main-
tained at effective levels for 24 hours .5 Tulobuterol
tape has less frequent adverse events than conven-
tional oral tulobuterol preparations, and when used at
bedtime can prevent a marked drop in peak expira-
tory flow (PEF) early in the morning by exerting a
bronchodilator effect for 24 hours . 6-10 Tulobuterol
tape is now commonly used in Japan as a long-acting
β2-agonist, while in the United States and Europe the
most frequently used long-acting β2-agonists are in-
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Table 1 Demographic and Clinical Characteristics at Baseline
Treatment Groups
Variables
2 mg (n＝123)1 mg (n＝116)
Age, yr
(1.3) 52.6(1.5) 53.1Mean (SE)
19-7720-78Range
Gender, No. (%)
(48) 59(51) 59Female
(52) 64(49) 57Male
Body height, cm
(0.8)160.0(0.7)159.6Mean (SE)
139-180140-178Range
Body weight, kg
(1.0) 59.2(1.0) 60.2Mean (SE)
36-9938-90Range
(9.0)332.4b)(9.0)328.4a)Mean (SE) morning PEF, L/min 
(9.4)355.7b)(9.2)351.3c)Mean (SE) evening PEF, L/min 
Mean (range) inhaled corticosteroid use, μg/day
(200-1,600)571(400-800)667Budesonide
(100-800)495(200-800)520Fluticasone
(200-1,200)504(150-1,600)627Beclomethasone
a): n＝116, b): n＝119, c): n＝114.
haled salmeterol and formoterol, the efficacy of which
is maintained through sustained binding to β2 recep-
tors.11-13
One of the important features of long-acting β2-
agonists is their additive effects when used with in-
haled corticosteroids, which have been observed with
both salmeterol and formoterol.14-21 However, the ef-
fects of tulobuterol tape administered together with
inhaled corticosteroids have not yet been investi-
gated . In the present study , we administered tu-
lobuterol tape at doses of 1 or 2 mgday to patients
with persistent asthma already using inhaled corti-
costeroids in order to evaluate its efficacy as a long-
acting β2-agonist and to compare its effects at two dif-
ferent doses.
METHODS
This was a multicenter, double-blind, parallel-group
comparative study designed to examine the efficacy
and safety of tulobuterol tape of 2 mgday and 1 mg
day over a 4-week treatment period in patients with
persistent asthma currently treated with inhaled corti-
costeroids . The study was conducted at 35 clinical
centers in Japan . Blinding was ensured using a
double-dummy technique in which patients received
either tulobuterol tape 1 or 2 mg and the correspond-
ing placebo.
PATIENT POPULATION
Male patients and nonpregnant or nonlactating fe-
male patients16 years old were eligible if they had
had a diagnosis of asthma as defined by the American
Thoracic Society22 for at least 6 months and had used
inhaled corticosteroids at a constant dosage for at
least 4 weeks prior to screening with short-acting β2-
agonists as needed (more than 4 puffs a week). Writ-
ten informed consent was obtained from each patient,
and the study was approved by the Institutional Re-
view Board at each center.
STUDY DESIGN
After an initial screening visit , during which study
participants underwent a physical examination and a
relevant medical history, eligible patients were asked
to use a standard peak flowmeter (Mini Wright ;
Clement Clark International Ltd ; Harlow , UK ) to
measure PEF daily in the morning and at bedtime,
and to record the highest of three-time forced exhala-
tion as well as symptoms and medications on daily di-
ary cards during a 14-day run-in period. Patients were
allocated at random to treatment with 1 mgday or
2 mgday of tulobuterol tape , when their PEF in-
creased by  15% after inhalation of short-acting β2-
agonists at the usual dose during the run-in period
andor their mean PEF at bedtime was 15% higher
than that in the morning during the week before ran-
domization. Patients were allowed to use salbutamol
as required for symptom control but no other sym-
pathomimetic agents. No oral or injected corticoster-
oids were allowed throughout the study. When pa-
tients received xanthines, anticholinergics, antialler-
gics, Chinese herbal medicines or expectorants dur-
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Fig. 1 Increase in morning PEF (upper panel) and evening 
PEF (lower panel) after administration of tulobuterol tape. 
Symbols and bars represent means and SE, respectively. 
**Significant diference between the point and baseline (P＜
0.01). †Significant diference between 1 mg treatment group 
(square) and 2 mg treatment group (circle) (P＜0.05).
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ing the run-in period, the same dosage and method of
administration were continued throughout the trial to
prevent bias. In addition, the same dosage of inhaled
corticosteroids and rescue use of inhaled short-acting
β2-agonists were continued throughout the trial. No
patient experienced exacerbation of asthma or an up-
per respiratory tract infection during the 4-week pe-
riod prior to the study.
STATISTICAL ANALYSIS
The primary efficacy variable was morning PEF. The
mean morning PEF value during the final week of the
treatment period was compared with that during the
last week prior to randomization. Improvement was
compared between the two groups using Wilcoxon’s
two-sample test . Secondary efficacy measures con-
sisted of changing PEF, asthma symptoms, distur-
bance of activities of daily living (ADL) and sleep, and
supplemental use of β2-agonists . Weekly averages
(mean ± standard deviation (SD)) of PEF in each
group were obtained during the final week of the run-
in period and throughout the treatment period. Stu-
dent’s two-sample test was used to compare changes
in PEF from baseline values between the two groups,
and Student’s one-sample test to compare changes in
PEF during the treatment period from baseline in
each group. For asthma symptoms, disturbance of
ADL and sleep, and supplemental β2-agonists use, the
t-test and paired t-test were used for analyses of differ-
ences between the two groups and within each
group, respectively. All statistical tests were two-side
at an a level of 0.05.
RESULTS
DEMOGRAPHICS
A total of 116 patients used tapes containing tu-
lobuterol at a dose of 1 mgday and 123 patients at a
dose of 2 mgday. As shown in Table 1, the two treat-
ment groups had similar demographic and clinical
characteristics at baseline.
PEF
Mean baseline morning PEF was comparable be-
tween the two groups (328.4 Lmin vs. 332.4 Lmin in
the 1 mgday and 2 mgday groups, respectively).
During the 4-week treatment period, patients in the
2 mgday group had significantly greater increases in
mean morning PEF (35.9 Lmin) compared with the
1 mgday group (23.8 Lmin, p < 0.05). Significantly
greater improvements in morning PEF (Fig. 1，upper
panel) were noted in the 2 mgday group within the
first week of treatment, and the superior bronchodi-
lating properties of the 2 mgday dose remained sig-
nificantly greater than those of the 1 mgday dose
throughout the study period. Significantly greater im-
provements in evening PEF (Fig . 1, lower panel )
were noted in the 2 mgday group within the first
week of treatment, and the bronchodilating effects of
2 mgday were persistently stronger than those ob-
served with the 1 mgday dose throughout the treat-
ment period, though the differences between them
were not statistically significant.
ASTHMA SYMPTOMS, DISTURBANCE OF ADL
AND SLEEP, AND SUPPLEMENTAL USE OF β2-
AGONISTS
Asthma symptoms, disturbance of ADL and sleep ,
and supplemental use of β2-agonists over the 4-week
study period are shown in Table 2. In both groups,
the number of symptom-free days significantly in-
creased compared with the baseline value, although
the number of symptom-free nights did not. Although
patients in neither group reported disturbance of
ADL or sleep at baseline, the number of days with
disturbance of sleep per week was significantly de-
creased in the 1 mgday group compared with base-
line. In both groups, daytime and nighttime supple-
mental use of β2-agonists significantly decreased
from baseline, and the number of rescue-free days
and nights significantly increased from baseline .
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Table 2 Baseline and mean change from baseline in symptom scores and β-stimulant use over 4 weeks of treatment with 
1 mg or 2mg Tulobuterol tape
p 
Value
(t-test)
Treatment Groups
Variables 2 mg (n＝123)1 mg (n＝116)
ChangeBaselineChangeBaseline
1.000(0.20)*0.52 (0.27)4.11 (0.23)*0.65 (0.29)4.10 No. of symptom-free days per week
1.000(0.20)0.27 (0.24)5.18 (0.22)0.56 (0.28)4.58 No. of symptom-free nights per week
1.000(0.12)0.10 (0.15)6.43 (0.15)0.07 (0.18)6.21 No. of days not disturbed ADL per week
0.100(0.09)0.04 (0.13)6.50 (0.17)*0.48 (0.17)6.26 No. of nights not disturbed sleep per week
1.000(0.18)**0.97 (0.25)4.66 (0.18)**0.99 (0.26)4.62 No. of rescue-free days per week
1.000(0.16)*0.47 (0.22)5.58 (0.17)**0.54 (0.22)5.72 No. of rescue-free nights per week
1.000(0.67)*－2.01 (1.05)5.14 (0.61)**－2.68 (1.16)6.43 No. of pufs per week
1.000(0.31)*－0.83 (0.38)2.12 (0.28)*－0.80 (0.33)1.70 No. of pufs per week (night time)
Date are presented as the mean (SE). Baseline value is the average for the 7 days immediately prior to treatment with tulobuterol-tape.
*: p＜0.05 (student’ spaired t-test) compared with Baseline. **: p＜0.01 (student’ spaired t-test) compared with Baseline.
There was no difference between groups in daytime
and nighttime supplemental use of β2-agonists and
numbers of rescue-free days and nights.
ADVERSE EFFECTS AND SYMPTOMS ASSOCI-
ATED WITH ASTHMA
The percentages of patients reporting at least one
drug-related adverse event , except skin reaction at
treatment sites, were comparable in the two groups
(14.7% in the 1 mgday group and 13.8% in the 2 mg
day group) . The drug-related adverse events most
frequently reported were palpitations ( 7% in the
1 mgday group and 6% in the 2 mgday group) and
tremor (3% in the 1 mgday group and 6% in the 2
mgday group). All other drug-related events, occur-
ring in > 1% of patients, were chest pain, headache
and thirst in the 1 mgday group and facial flushing
and thirst in the 2 mgday group. The percentages of
patients reporting local adverse reactions were also
comparable in the two groups (24.1% in the 1 mgday
group and 18.7% in the 2 mgday group). The local
adverse events most frequently reported were itching
(16% in the 1 mgday group and 14% in the 2 mgday
group), redness (10% in the 1 mgday group and 4%
in the 2 mgday group), and dermatitis (8% in the 1
mgday group and 2% in the 2 mgday group). Pain
was reported in the 2 mgday group as a local event
occurring in < 1% of patients . No patient exhibited
symptoms associated with mild increase in CPK, al-
though increase in CPK was observed in 10% and 12%
of patients in the 1 and 2 mgday groups, respec-
tively. In both groups, only 1 patient withdrew from
the study due to exacerbation of asthma.
DISCUSSION
In the present study, we compared the effects of 4-
week treatment with 1 mgday or 2 mgday of tu-
lobuterol tape once a day in patients with persistent
asthma which was not fully controlled despite regular
inhalation of corticosteroids . We found that tu-
lobuterol tape at both 1 mgday and 2 mgday signifi-
cantly increased the mean morning and night PEF
throughout the treatment period , compared with
baseline values . We therefore conclude that tu-
lobuterol tape acts as a long-acting β2-agonist that can
be used in the treatment of persistent asthma, since it
has add-on effects when administered together with
inhaled corticosteroids.
Although tulobuterol is a short-acting β2-agonist
with regard to its affinity of binding to receptors, tu-
lobuterol tape is a sustained-release preparation that
uses a transdermal therapeutic system. Peak concen-
tration of tulobuterol in the blood was found in the
early morning and effective concentration in the
blood is maintained for 24 hours, when it is applied at
bedtime once daily . 5 Crompton et al. reported that
once-daily oral bambuterol is a convenient and alter-
native to twice-daily inhaled salmeterol for treating
nocturnal asthma.23 Therefore, regardless of their af-
finity of binding to β2 receptors, it appears that β2-
agonists , which have long-term bronchodilating ef-
fects, behave as long-acting β2-agonists in the treat-
ment of asthma.
Since we used improvement of PEF as the primary
outcome measure in the present study, patients were
enrolled when their PEF increased by 15% after in-
halation of short-acting β2-agonists at the usual doses
during the run-in period andor their mean PEF at
bedtime was 15% higher than that in the morning
during the week before randomization. As a conse-
quence , many patients were asymptomatic and in-
haled a few supplemental β2-agonists during the run-
in period. This might be the reason for the lack of sig-
nificant decreases in improvement of asthmatic symp-
toms and disturbance of ADL and sleep throughout
the 4-week study , although supplemental daytime
618 Allergology International Vol 54, No4, 2005 www.jsaweb.jp
Tamura G et al.
and nighttime use of β2-agonists significantly de-
creased in both groups．
A double-blind comparative study of tulobuterol
tape with tulobuterol hydrochloride tablets has con-
firmed that tulobuterol tape is superior in clinical effi-
cacy to the conventional oral preparation of tu-
lobuterol, with milder and less frequent systemic ad-
verse effects such as palpitations and tremors.6 Tu-
lobuterol tape possesses several advantages over in-
haled preparations, including availability for use in in-
fants and elderly individuals who cannot inhale
drugs, simple confirmation of drug use by visual in-
spection of applied tape , and good compliance be-
cause of its once-daily regimen. The 2003 Japanese
Asthma Prevention and Management Guidelines rec-
ommended that tulobuterol tape be used as a long-
term controller agent for persistent asthma . Al-
though , in our previous clinical study , tulobuterol
tape did not exhibit decrease in efficacy and had no
severe adverse events with long-term administration
over 1 year,24 we need to examine the effects and ad-
verse effects of the tape for a prolonged period.
In summary , tulobuterol tape exerted add-on ef-
fects to inhaled corticosteroids. Although both the 1
and 2 mgday tapes significantly increased mean
morning and night PEF compared with baseline val-
ues, the increase in mean morning PEF was signifi-
cantly greater in the 2 mgday group. No patient ex-
perienced serious adverse events during the study.
Neither the nature nor the incidence of adverse
events differed significantly between the two groups.
We conclude that tulobuterol tape is a convenient and
effective long-acting β2-agonist for the treatment of
persistent asthma.
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